ILLUMINA INC (ILMN)
US4523271090 - Common Stock
ILMN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. While ILMN seems to be doing ok healthwise, there are quite some concerns on its profitability. ILMN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ILMN was profitable.
In the past year ILMN had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ILMN reported negative net income in multiple years.
In the past 5 years ILMN always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of ILMN (-12.84%) is comparable to the rest of the industry.
ILMN has a Return On Equity (-22.48%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.84% | ||
| ROE | -22.48% | ||
| ROIC | N/A |
ROA(3y)-14.14%
ROA(5y)-4.02%
ROE(3y)-26.62%
ROE(5y)-8.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ILMN's Gross Margin of 61.36% is amongst the best of the industry. ILMN outperforms 86.21% of its industry peers.
ILMN's Gross Margin has declined in the last couple of years.
ILMN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.6%
GM growth 5Y-2.46%
2. Health
2.1 Basic Checks
ILMN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ILMN has been increased compared to 1 year ago.
ILMN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ILMN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.78 indicates that ILMN is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.78, ILMN is in line with its industry, outperforming 56.90% of the companies in the same industry.
The Debt to FCF ratio of ILMN is 4.07, which is a neutral value as it means it would take ILMN, 4.07 years of fcf income to pay off all of its debts.
ILMN has a Debt to FCF ratio of 4.07. This is in the better half of the industry: ILMN outperforms 77.59% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that ILMN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.26, ILMN is in line with its industry, outperforming 48.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 4.07 | ||
| Altman-Z | 2.78 |
ROIC/WACCN/A
WACC11.95%
2.3 Liquidity
A Current Ratio of 1.75 indicates that ILMN should not have too much problems paying its short term obligations.
The Current ratio of ILMN (1.75) is worse than 72.41% of its industry peers.
A Quick Ratio of 1.36 indicates that ILMN should not have too much problems paying its short term obligations.
The Quick ratio of ILMN (1.36) is worse than 74.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.75 | ||
| Quick Ratio | 1.36 |
3. Growth
3.1 Past
The earnings per share for ILMN have decreased strongly by -22.12% in the last year.
Measured over the past years, ILMN shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -31.38% on average per year.
ILMN shows a small growth in Revenue. In the last year, the Revenue has grown by 1.03%.
Measured over the past years, ILMN shows a small growth in Revenue. The Revenue has been growing by 6.21% on average per year.
EPS 1Y (TTM)-22.12%
EPS 3Y-42.18%
EPS 5Y-31.38%
EPS Q2Q%12.5%
Revenue 1Y (TTM)1.03%
Revenue growth 3Y11.62%
Revenue growth 5Y6.21%
Sales Q2Q%-1.01%
3.2 Future
Based on estimates for the next years, ILMN will show a very strong growth in Earnings Per Share. The EPS will grow by 59.74% on average per year.
ILMN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.66% yearly.
EPS Next Y-17.21%
EPS Next 2Y72.8%
EPS Next 3Y55.29%
EPS Next 5Y59.74%
Revenue Next Year0.79%
Revenue Next 2Y3.8%
Revenue Next 3Y5.25%
Revenue Next 5Y9.66%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 118.50, the valuation of ILMN can be described as expensive.
Based on the Price/Earnings ratio, ILMN is valued a bit cheaper than 65.52% of the companies in the same industry.
ILMN is valuated expensively when we compare the Price/Earnings ratio to 28.05, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 40.14, the valuation of ILMN can be described as expensive.
Based on the Price/Forward Earnings ratio, ILMN is valued a bit cheaper than the industry average as 63.79% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.07, ILMN is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 118.5 | ||
| Fwd PE | 40.14 |
4.2 Price Multiples
62.07% of the companies in the same industry are more expensive than ILMN, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ILMN indicates a somewhat cheap valuation: ILMN is cheaper than 70.69% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 45.39 | ||
| EV/EBITDA | 43.94 |
4.3 Compensation for Growth
ILMN's earnings are expected to grow with 55.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y72.8%
EPS Next 3Y55.29%
5. Dividend
5.1 Amount
No dividends for ILMN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ILLUMINA INC
NASDAQ:ILMN (5/31/2024, 7:00:02 PM)
After market: 104.3 +0.02 (+0.02%)104.28
+3.23 (+3.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap16.61B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 118.5 | ||
| Fwd PE | 40.14 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.84% | ||
| ROE | -22.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.36% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.75 | ||
| Quick Ratio | 1.36 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-22.12%
EPS 3Y-42.18%
EPS 5Y
EPS Q2Q%
EPS Next Y-17.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.03%
Revenue growth 3Y11.62%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y